| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() FDA Approves Quetiapine Fumarate for the Treatment of Bipolar Depression, Mania NEW YORK -- October 10, 2008 -- The US Food and Drug Administration (FDA) has approved once-daily quetiapine fumarate (Seroquel XR) extended-release tablets for the acute treatment of the depressive episodes associated with bipolar disorder, the manic and mixed episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder as adjunctive therapy to lithium or divalproex. "When people think about bipolar disorder it is important to remember how debilitating the depressive episodes of the disease can be. In fact, in the long term, patients with bipolar disorder experience depressive symptoms 3 times longer than manic symptoms," said Trisha Suppes, MD, Stanford University Medical Center, Stanford, California, and VA Palo Alto Health Care System, Palo Alto, California. "With the approval of [extended release quetiapine fumarate] for the treatment of bipolar depression and mania, we have a once-daily treatment that has been proven to help control the depressive and manic symptoms of bipolar disorder."
SOURCE: AstraZeneca
|